Loading
A phase 2 trial of pembrolizumab, carboplatin and paclitaxel / nab-paclitaxel in triple-negative breast cancer, run by Tel Aviv Medical Center, not yet recruiting.
Neoadjuvant Pembrolizumab, Carboplatin and Paclitaxel in Triple-negative Breast Cancer is a phase 2, interventional study registered as NCT06407310 by Tel Aviv Medical Center, with a registry enrolment figure of 25 participants, started 2024-07-01 and due to reach its primary completion in 2027-04-01. Interventions recorded: Pembrolizumab; Carboplatin; Paclitaxel. Conditions listed: Triple Negative Breast Cancer. Triple-negative eligibility wording from the registry: "Male/female participants who are at least 18 years of age on the day of signing informed consent with a histologically confirmed diagnosis of stage I or II TNBC". No results are recorded here; the registry entry is the source.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Platinum agents, Paclitaxel / nab-paclitaxel and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Platinum agents, Paclitaxel / nab-paclitaxel and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Platinum agents, Paclitaxel / nab-paclitaxel and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Platinum agents, Carboplatin and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Platinum agents, Paclitaxel / nab-paclitaxel and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Platinum agents, Paclitaxel / nab-paclitaxel and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Platinum agents, Paclitaxel / nab-paclitaxel and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Platinum agents, Paclitaxel / nab-paclitaxel and the tag tnbc-deep-dive.